BOC Sciences Hosts Vascular Nano-Delivery Webinar Featuring UPenn's Dr. Muzykantov

BOC Sciences is hosting a webinar titled "Vascular Nano-Delivery Using Tropism and Targeting" featuring Dr. Muzykantov of the University of Pennsylvania to discuss current knowledge on vascular nanomedicine. The session will focus on how drug delivery systems can be optimized to reach specific vascular targets, addressing one of the most pressing hurdles in pharmaceutical research today: achieving efficient and precise drug delivery. Dr. Muzykantov, Founding Co-Director of the PSOM/SEAS Center for Targeted Therapeutics and Translational Nanomedicine at the University of Pennsylvania and author of over 330 publications, will discuss both cognizant targeting based on known binding sites and fortuitous tropism, where delivery systems exhibit unexpected affinity or homing behaviors.

The webinar represents BOC Sciences' strategic commitment to connecting its community with visionary researchers shaping the future of medicine. As a leading drug discovery CDMO, BOC Sciences offers comprehensive solutions for designing, developing, and enhancing critical delivery systems that help scientists navigate biological barriers while improving drug bioavailability, safety, stability, and effectiveness. The company's expertise in advanced delivery carriers encompasses liposomes, nanoparticles, and microspheres, ensuring researchers have access to quality materials and technical support needed to expedite projects from bench to bedside.

This collaboration exemplifies BOC Sciences' commitment to engaging with academia to address the latest challenges and advancements in targeted nanomedicine. The virtual event, scheduled for December 12th, 2025 at 10:00 AM EST, provides an opportunity for professionals to connect with insights that will impact the future of drug delivery research. Registration for this defining event is now open through their online registration portal at https://www.bocsci.com/webinar-registration. BOC Sciences shares a vision with researchers for the successful development of the next generation of targeted nanomedicines, facilitating knowledge-sharing with leading scientific minds to accelerate scientific discovery and therapeutic development.